Preload Therapeutics is pursuing cardiometabolic reprogramming via FGF21 agonism.

Preload has in-licensed a late development ready asset: PTX-001 (aka NGM-313/MK-3655) —the only FGF21 agonist antibody in later stage clinical development. Clinical data from six trials, >350 patients, up to 1 year dosing supports best in class safety & PK profile - key differentiators within the class. Downstream PD/target engagement observed which signal activity across multiple axes of HFpEF biology. Preload is targeting a $60M Series A in 1H2026 to fund completion of the PoC study in HFpEF, with ability to pivot post-PoC to late stage registrational trials based on the existing clinical safety data package from prior studies. Preload is actively seeking pharma partners to advance the asset post-PoC.